EAGLE PHARMACEUTICALS INC's ticker is EGRX and the CUSIP is 269796108. A total of 141 filers reported holding EAGLE PHARMACEUTICALS INC in Q3 2016. The put-call ratio across all filers is 0.34 and the average weighting 0.9%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q2 2023 | $491,832 | -31.5% | 25,300 | 0.0% | 0.00% | – |
| Q1 2023 | $717,761 | -15.0% | 25,300 | -12.5% | 0.00% | -100.0% |
| Q4 2022 | $844,747 | +14.2% | 28,900 | +3.2% | 0.00% | 0.0% |
| Q3 2022 | $740,000 | -40.5% | 28,000 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $1,244,000 | -3.3% | 28,000 | +7.7% | 0.00% | 0.0% |
| Q1 2022 | $1,287,000 | +3.6% | 26,000 | +6.6% | 0.00% | 0.0% |
| Q4 2021 | $1,242,000 | -8.7% | 24,400 | 0.0% | 0.00% | 0.0% |
| Q3 2021 | $1,361,000 | +30.4% | 24,400 | 0.0% | 0.00% | 0.0% |
| Q2 2021 | $1,044,000 | -1.1% | 24,400 | -3.6% | 0.00% | 0.0% |
| Q1 2021 | $1,056,000 | -14.1% | 25,300 | -4.2% | 0.00% | 0.0% |
| Q4 2020 | $1,229,000 | +9.6% | 26,400 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $1,121,000 | -9.8% | 26,400 | +1.9% | 0.00% | 0.0% |
| Q2 2020 | $1,243,000 | +27.5% | 25,900 | +22.2% | 0.00% | 0.0% |
| Q1 2020 | $975,000 | -22.0% | 21,200 | +1.9% | 0.00% | 0.0% |
| Q4 2019 | $1,250,000 | +6.2% | 20,800 | 0.0% | 0.00% | 0.0% |
| Q3 2019 | $1,177,000 | +1.6% | 20,800 | 0.0% | 0.00% | 0.0% |
| Q2 2019 | $1,158,000 | +7.7% | 20,800 | -2.3% | 0.00% | 0.0% |
| Q1 2019 | $1,075,000 | +25.3% | 21,300 | 0.0% | 0.00% | 0.0% |
| Q4 2018 | $858,000 | -40.2% | 21,300 | +2.9% | 0.00% | -50.0% |
| Q3 2018 | $1,435,000 | -8.4% | 20,700 | 0.0% | 0.00% | 0.0% |
| Q2 2018 | $1,566,000 | +109.4% | 20,700 | +45.8% | 0.00% | +100.0% |
| Q1 2018 | $748,000 | -1.4% | 14,200 | 0.0% | 0.00% | 0.0% |
| Q4 2017 | $759,000 | -10.4% | 14,200 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $847,000 | -24.4% | 14,200 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $1,120,000 | -12.3% | 14,200 | -7.8% | 0.00% | -50.0% |
| Q1 2017 | $1,277,000 | +4.5% | 15,400 | 0.0% | 0.00% | 0.0% |
| Q4 2016 | $1,222,000 | +20.4% | 15,400 | +6.2% | 0.00% | 0.0% |
| Q3 2016 | $1,015,000 | +73.2% | 14,500 | -4.0% | 0.00% | +100.0% |
| Q2 2016 | $586,000 | +9.5% | 15,100 | +10.2% | 0.00% | 0.0% |
| Q1 2016 | $535,000 | -45.6% | 13,700 | +23.4% | 0.00% | -50.0% |
| Q4 2015 | $984,000 | +19.7% | 11,100 | 0.0% | 0.00% | 0.0% |
| Q3 2015 | $822,000 | +7.0% | 11,100 | +16.8% | 0.00% | 0.0% |
| Q2 2015 | $768,000 | – | 9,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| ProQuest Associates IV LLC | 3,652,284 | $302,920,000 | 91.10% |
| Hudson Executive Capital LP | 1,901,200 | $157,686,000 | 21.62% |
| JW Asset Management, LLC | 525,755 | $43,606,000 | 9.08% |
| Cormorant Asset Management, LP | 200,000 | $16,588,000 | 2.41% |
| Park West Asset Management LLC | 488,128 | $40,485,000 | 2.36% |
| Opaleye Management Inc. | 50,000 | $4,147,000 | 2.06% |
| Ranger Investment Management | 283,954 | $23,551,000 | 1.71% |
| Pier Capital, LLC | 74,732 | $6,198,000 | 1.06% |
| Bellevue Group AG | 67,700 | $5,615,000 | 0.75% |
| Orbimed Advisors | 671,000 | $55,653,000 | 0.63% |